


ALKEM Daily Closing One Year Price Chart



Name	Mar Cap (Rs. Cr.)	P/E	ROE	Sales(G) QoQ	Sales(G) QYoY	PAT(G) QoQ	PAT(G) QYoY
un Pharmaceutical Industries Ltd.	418768	133	12.9%	20.8%	22.0%	36.8%	49.8%
Divi's Laboratories Ltd.	156447	75.5	12.0%	-0.22%	27.0%	14.7%	65.9%
Cipla Ltd.	122019	26.2	15.3%	4.1%	13.5%	22.1%	41.3%
Torrent Pharmaceuticals Ltd.	110144	60.4	20.2%	-2.34%	12.0%	5.43%	63.3%
Mankind Pharma Limited	106748	55.2	19.7%	-5.26%	8.48%	-34.4%	-10.0%

Aspect	Commentary
Revenue	Revenue grew 4.08% YoY to Rs.9507 Cr, driven by domestic and international sales. However, QoQ revenue declined by 2.89%, reflecting challenges in quarterly performance. The company's focus on chronic therapies and trade generics supports sustainable growth.
Profit & Loss	Operating profit margin stands at 24.5%, showcasing strong cost management. PAT grew 57.38% YoY, indicating improved profitability. Quarterly PAT growth of 5.3% reflects steady operational efficiency despite revenue decline.
Profitability Matrix	Net profit margin of 18.5% and EBITDA margin of 23.92% highlight robust profitability. EPS growth of 33.56% YoY underscores shareholder value creation. Operational metrics reflect efficient cost control and strategic execution.
Valuation Matrix	Trailing P/E of 26.7 and PEG ratio of 1.52 suggest moderate valuation relative to growth potential. EV/EBITDA of 21.1 indicates premium valuation, supported by strong profitability. Dividend yield of 0.8% adds to investor appeal.
Growth (YoY)	Sales growth of 4.08% YoY reflects steady expansion, while PAT growth of 57.38% highlights improved margins and operational efficiency. EPS growth of 33.56% demonstrates strong earnings performance, driven by strategic initiatives.
Growth (QoQ)	QoQ sales declined by 2.89%, reflecting short-term challenges. However, PAT grew 5.3%, supported by cost efficiencies. QYoQ PAT growth of 35.47% indicates resilience in profitability despite revenue pressures.
Capital Allocation	RoE of 18.1% and RoCE of 18.4% highlight efficient capital utilization. RoIC of 25% underscores strong returns on invested capital. Cash equivalents of Rs.1284 Cr provide liquidity for strategic investments and operations.
Holdings	Promoter holding of 55.7% reflects strong ownership confidence. FII and DII holdings of 9.4% and 19.4%, respectively, indicate institutional interest. Public holding of 16% ensures diversified ownership structure.
Leverage	Debt/equity ratio of 0.05 reflects minimal leverage, ensuring financial stability. Debt of Rs.619 Cr is manageable, supported by healthy cash reserves. Market cap of Rs.59765 Cr and enterprise value of Rs.59100 Cr highlight strong market positioning.